BOC Sciences is committed to providing one-stop antibody-drug conjugate (ADC) solutions to global customers, covering the full service chain from early discovery and process development to preclinical research. Leveraging advanced technology platforms, a rich library of toxins and linkers, an experienced R&D team, and a high-standard quality control system, we offer solid support for the rapid development and translation of ADC drugs. Through standardized and modular service processes, we ensure high controllability and transparency for each project. BOC Sciences not only has the capability to efficiently construct ADC prototypes but also enables a smooth transition from laboratory scale to pilot production, accelerating the clinical advancement of candidate molecules. We are your trusted partner in ADC development.
Target screening and antibody design have high entry thresholds, which impact the targeting and internalization efficiency of ADCs. BOC Sciences has a mature antibody screening and humanization platform that enables the customization of high-affinity, low-immunogenicity antibody molecules to enhance targeting performance.
The design of linker structures is complex and determines the precision of drug release and pharmacological safety. We offer various types of cleavable linkers and non-cleavable linkers and support intelligent structural optimization to ensure good stability and controllable release performance of ADCs in vivo.
Payload drugs are highly toxic, and their synthesis and handling require strict safety controls. BOC Sciences possesses a mature platform for the synthesis of highly potent molecules and a safe operating system, supporting kilogram-scale custom synthesis and purification of various cytotoxins.
The conjugation process imposes stringent requirements on drug-to-antibody ratio (DAR) control and molecular homogeneity. We have developed multiple conjugation strategies and DAR optimization technologies to precisely control drug loading and conjugation sites, thereby improving product consistency and stability.
In response to the characteristics of ADC projects, BOC Sciences has built an integrated development framework encompassing early discovery – process development – preclinical research. With technological depth and platform integration at its core, we help clients address challenges across the entire ADC R&D pipeline.
Target Analysis and Antibody Screening
Linker and Payload Screening
Conjugation Strategy Development
Prototype ADC Construction and Functional Validation
GMP Material Development
Conjugation Reactions and DAR Control
Purification and Formulation Development
Analytical Method Development
In Vitro Pharmacology and Mechanism Studies
In Vivo Pharmacology and PK/PD
Toxicology Studies
Regulatory Filing Support
Based on years of biopharmaceutical experience, BOC Sciences has built an integrated ADC R&D engine that covers all aspects from molecular design and critical raw material preparation to conjugation strategy development and analytical quality control. Our platform is highly flexible, supporting both customized development and high-standard industrial production, greatly improving the efficiency and controllability of ADC projects.
As a critical factor in ADC efficacy, safety, and stability, BOC Sciences has established a chemistry platform encompassing cleavable linkers (e.g., acid-sensitive, enzyme-cleavable, reduction-sensitive) and non-cleavable linkers, with full-service capabilities from design and synthesis to purification. We also support customized linker structures to meet client needs for precise drug release.
For commonly used microtubule inhibitors (e.g., MMAE, DM1) and DNA-damaging agents (e.g., PBD, Calicheamicin), BOC Sciences provides complete systems for synthesis, modification, storage, and handling, accommodating process scale-up from milligram to kilogram levels. We can also assist clients with the targeted synthesis and functional validation of novel cytotoxic agents.
BOC Sciences offers traditional Lysine conjugation, Cysteine conjugation, and site-specific conjugation strategies, as well as new techniques such as Enzymatic Conjugation (e.g., Transglutaminase, Sortase A) and Click Chemistry. Through DAR control and structural uniformity evaluation, we ensure ADCs with superior stability and predictability.
ADC development relies heavily on analytical characterization. BOC Sciences has established a complete ICH-compliant analytical system, including HPLC, LC-MS, HIC, SEC, UV, SDS-PAGE, etc., for comprehensive characterization of antibodies, linkers, drug loading (DAR), purity, aggregates, and free toxins. We also provide support for CMC development, including analytical method establishment and validation.
To support varying scale requirements from preclinical to clinical stages, BOC Sciences is equipped with advanced GMP-compliant facilities to support ADC pilot scale-up, raw material batch preparation, process transfer, and small-scale production. Our production system complies with US FDA and EMA standards, ensuring a solid foundation for clients' subsequent IND/CTA submissions and clinical advancement.
BOC Sciences has developed a range of next-generation ADC platforms, including FDCs, BsADCs, DACs, dual-payload, NDCs, and SDCs. These platforms support customized structures, linker screening, and payload strategies, enabling tailored solutions for diverse targets and indications while enhancing the precision and innovation of ADC candidates.
We have established a comprehensive end-to-end platform encompassing target discovery, antibody screening, linker design, payload synthesis, conjugation process, and quality analysis, providing one-stop ADC development services.
We tailor molecular structures, conjugation methods, and process parameters according to client project requirements, supporting diverse conjugation strategies and highly potent drug structures to achieve differentiated ADC designs.
Equipped with high-throughput analytical instruments and a well-established methodological system, we comprehensively support the characterization and control of key quality attributes such as DAR determination, purity analysis, and impurity identification.
We operate dedicated facilities for the synthesis of highly potent drugs and possess extensive experience and safety management procedures for handling toxic and reactive compounds, ensuring operational compliance and product quality.
Our experienced project management team maintains effective communication with clients, ensuring clearly defined milestones, controllable progress, and rapid response to technical changes and development needs.
We support process transfer and pilot production from preclinical to clinical sample preparation and provide a GMP-compliant system to robustly support clients' IND/CTA filings.
Based on client goals and our accumulated technical database, we formulate customized ADC development plans. Through cross-assessment of target expression, linker types, and payload stability, we provide scientific guidance and risk prediction for subsequent experiments.
We rapidly construct multiple ADC prototype molecules and conduct DAR control, conjugation efficiency testing, and in vitro cytotoxicity screening to preliminarily validate druggability and structural feasibility of candidate molecules.
For the preferred ADC molecule, we optimize the conjugation process through systematic studies on parameters such as reaction conditions, raw material purity, and batch consistency. This ensures scalability and supports small-scale pilot preparation.
Utilizing high-standard analytical platforms, we conduct comprehensive quality evaluations covering purity, aggregates, free drug, DAR, residual solvents, and more. This is accompanied by the establishment and validation of analytical methods to meet regulatory requirements.
We assist clients in conducting in vivo efficacy evaluations and preliminary toxicological studies of ADC molecules, providing data on therapeutic efficacy and toxic side effects to support clinical development.
With our GMP-compliant processes, standardized analytical methods, and comprehensive research documentation, we offer technical support for IND submissions, including preparation of CMC documents, process control summaries, and analytical method validation data.
Yes. We provide GMP-compatible system support including raw material traceability, cleaning validation, standardized operating procedures (SOPs), and project transfer documentation to meet regulatory requirements for preclinical and clinical sample preparation.
Yes. BOC Sciences adopts a modular service process. Clients may choose any stage—such as early screening, linker optimization, toxin synthesis, or process development—for independent or joint development.
We assign a dedicated project manager to each project, who provides regular progress reports, raw data, and technical recommendations. This ensures transparent communication and high-quality, on-time project delivery.
We support a wide range of mainstream and innovative linkers (e.g., ester bonds, peptide bonds, thioether bonds, thiomaleimide, etc.) as well as various toxins including MMAE, DM1, PBD, SN-38. We also offer custom design and synthesis services upon request.
Absolutely. We accept client-supplied antibodies and drug molecules and offer tailored conjugation strategy development and process optimization services to ensure high conjugation efficiency, excellent stability, and scalable processes.
We have established a robust analytical platform utilizing technologies such as HIC, SEC, LC-MS, and UV-HPLC for systematic characterization and batch control of key quality attributes including DAR values, free drug content, aggregates, and purity.
